Natural killer cell subsets and natural killer-like T-cell populations in benign and neoplastic B-cell proliferations vary based on clinicopathologic features

Human Pathology

Volumn 42, Issue 5, 2011, Pages 679-687

  Gibson, Sarah E ^a   Swerdlow, Steven H ^a   Felgar, Raymond E ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

Author keywords

B cell non Hodgkin lymphoma; Flow cytometry; NK cells; NKT cells

Indexed keywords

CD16 ANTIGEN; CD3 ANTIGEN; CD56 ANTIGEN;

ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; BENIGN CHILDHOOD EPILEPSY; BENIGN TUMOR; CANCER STAGING; CELL INFILTRATION; CHRONIC LYMPHATIC LEUKEMIA; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; LYMPHOCYTE PROLIFERATION; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; T LYMPHOCYTE SUBPOPULATION;

ANTIGENS, CD; CELL PROLIFERATION; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; KILLER CELLS, NATURAL; LYMPHOCYTE SUBSETS; LYMPHOMA, B-CELL; LYMPHOMA, FOLLICULAR; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, NON-HODGKIN; NEOPLASM STAGING; SPLEEN; T-LYMPHOCYTES;

EID: 79954611525     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2010.07.023     Document Type: Article

References (35)

1. Burger J.A., Ghia P., Rosenwald A., and Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies Blood 114 2009 3367 3375
2. Reddy N., Hernandez-Ilizaliturri F.J., and Deeb G. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo Br J Haematol 140 2008 36 45 (Pubitemid 350233246)
3. Glas A.M., Knoops L., and Delahaye L. Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma J Clin Oncol 25 2007 390 398 (Pubitemid 350002987)
4. Farinha P., Masoudi H., and Skinnider B.F. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL) Blood 106 2005 2169 2174 (Pubitemid 41291735)
5. Taskinen M., Karjalainen-Lindsberg M.L., and Nyman H. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin- vincristine-prednisone Clin Cancer Res 13 2007 5784 5789 (Pubitemid 47591642)
6. Caligaris-Cappio F. Role of the microenvironment in chronic lymphocytic leukemia Br J Haematol 123 2003 380 388 (Pubitemid 37363477)
7. Palmer S., Hanson C.A., and Zent C.S. Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia Br J Haematol 141 2008 607 614 (Pubitemid 351667615)
8. Plonquet A., Haioun C., and Jais J.P. Peripheral blood natural killer cell count is associated with clinical outcome in patients with aaIPI 2-3 diffuse large B-cell lymphoma Ann Oncol 18 2007 1209 1215 (Pubitemid 47244368)
9. Kuriyama Y., Nakano M., and Kawanishi Y. Cytotoxic lymphocytes in the peripheral blood of patients with B cell lymphomas Leukemia 9 1995 2123 2126 (Pubitemid 26023800)
10. Tursz T., Dokhelar M.C., Lipinski M., and Amiel J.L. Low natural killer cell activity in patients with malignant lymphoma Cancer 50 1982 2333 2335 (Pubitemid 13244169)
11. Caligiuri M.A. Human natural killer cells Blood 112 2008 461 469
12. Oshimi K. Progress in understanding and managing natural killer-cell malignancies Br J Haematol 139 2007 532 544 (Pubitemid 350043813)
13. Tarazona R., DelaRosa O., and Alonso C. Increased expression of NK cell markers on T lymphocytes in aging and chronic activation of the immune system reflects the accumulation of effector/senescent T cells Mech Ageing Dev 121 2000 77 88 (Pubitemid 32115402)
14. Olteanu H., Schur B.C., Bredeson C., Atallah E., and Kroft S.H. Expression of natural killer receptors in T- and NK-cells: comparison of healthy individuals, patients with prior stem cell transplant, and patients undergoing chemotherapy Leuk Lymphoma 51 2010 481 487
15. Gluck W.L., Hurst D., and Yuen A. Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-Hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response Clin Cancer Res 10 2004 2253 2264 (Pubitemid 38445682)
16. Wu L., Adams M., and Carter T. Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells Clin Cancer Res 14 2008 4650 4656
17. S.H. Swerdlow, E. Campo, N.L. Harris, WHO classification of tumours of haematopoietic and lymphoid tissues 2008 IARC Lyon
18. Carbone P.P., Kaplan H.S., Musshoff K., Smithers D.W., and Tubiana M. Report of the committee on Hodgkin's disease staging classification Cancer Res 31 1971 1860 1861
19. The International Non-Hodgkin's Lymphoma Prognostic Factors Project A predictive model for aggressive non-Hodgkin's lymphoma N Engl J Med 329 1993 987 994
20. Solal-Céligny P., Roy P., and Colombat P. Follicular lymphoma international prognostic index Blood 104 2004 1258 1265 (Pubitemid 39166497)
21. Rai K.R., Sawitsky A., and Cronkite E.P. Clinical staging of chronic lymphocytic leukemia Blood 46 1975 219 234
22. de Romeuf C., Dutertre C.A., and Garff-Tavernier M. Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA/CD16 Br J Haematol 140 2008 635 643 (Pubitemid 351300917)
23. Lanier L.L., Le A.M., Phillips J.H., Warner N.L., and Babcock G.F. Subpopulations of human natural killer cells defined by expression of the Leu-7 (HNK-1) and Leu-11 (NK-15) antigens J Immunol 131 1983 1789 1796 (Pubitemid 13006894)
24. Nagler A., Lanier L.L., Cwirla S., and Phillips J.H. Comparative studies of human FcRIII-positive and negative natural killer cells J Immunol 143 1989 3183 3191 (Pubitemid 20010143)
25. Phillips J.H., and Lanier L.L.A. Model for the differentiation of human natural killer cells. Studies on the in vitro activation of Leu-11+ granular lymphocytes with a natural killer-sensitive tumor cell, K562 J Exp Med 161 1985 1464 1482 (Pubitemid 15046041)
26. Van den Hove L.E., Van Gool S.W., Vandenberghe P., Boogaerts M.A., and Ceuppens J.L. CD57+/CD28- T cells in untreated hemato-oncological patients are expanded and display a Th1-type cytokine secretion profile, ex vivo cytolytic activity and enhanced tendendy to apoptosis Leukemia 12 1998 1573 1582 (Pubitemid 28470442)
27. Harris N.L., and Bhan A.K. Distribution of T-cell subsets in follicular and diffuse lymphomas of B-cell type Am J Pathol 113 1983 172 180 (Pubitemid 13023453)
28. Farinha P., Al-Tourah A., and Gill K. The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation Blood 115 2010 289 295
29. Diaz J., Tubbs R., Stoler M., and Grogan T. Cytolytic (TIA-1+) tumor infiltrating lymphocytes in B cell non-Hodgkin's lymphomas Leuk Lymphoma 9 1993 91 94 (Pubitemid 23141045)
30. Hasselblom S., Sigurdadottir M., and Hansson U. The number of tumour-infiltrating TIA-1+ cytotoxic T cells but not FOXP3+ regulatory T cells predicts outcome in diffuse large B-cell lymphoma Br J Haematol 137 2007 364 373 (Pubitemid 46650261)
31. Westermann J., and Pabst R. Distribution of lymphocyte subsets and natural killer cells in the human body Clin Investig 70 1992 539 544
32. Witte T., Wordelmann K., and Schmidt R.E. Heterogeneity of human natural killer cells in the spleen Immunology 69 1990 166 170
33. Chinen H., Matsuoka K., and Sato T. Lamina propria c-kit+ immune precursors reside in human adult intestine and differentiate into natural killer cells Gastroenterology 133 2007 559 573 (Pubitemid 47187343)
34. Münz C. Non-cytotoxic protection by human NK cells in mucosal secondary lymphoid tissues Eur J Immunol 38 2008 2946 2948
35. Zhang L., Qian Z., and Cai Z. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo Am J Hematol 84 2009 553 559